Fetal and neonatal alloimmune thrombocytopenia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:853P61.0
Who is this for?
Show terms as
3Active trials23Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Fetal and neonatal alloimmune thrombocytopenia (FNAIT), also called neonatal alloimmune thrombocytopenia (NAIT or NAT), is a blood condition that affects babies before or shortly after birth. It happens when a mother's immune system makes antibodies against proteins on her baby's platelets — the tiny blood cells that help stop bleeding. This occurs because the baby inherits platelet proteins from the father that the mother does not have. Her immune system sees these proteins as foreign and attacks them, lowering the baby's platelet count to dangerously low levels. The most serious risk is bleeding, especially bleeding in the brain (intracranial hemorrhage), which can happen before birth or in the first days of life. Babies may be born with bruising, tiny red or purple spots on the skin called petechiae, or more serious internal bleeding. Some cases are mild, while others can be life-threatening or cause lasting brain injury. Treatment depends on how severe the condition is. Mothers in future pregnancies may receive intravenous immunoglobulin (IVIG) therapy to reduce antibody levels and protect the baby. Newborns with very low platelet counts may receive platelet transfusions. With careful monitoring and treatment, many babies do well, but early diagnosis is critical to prevent serious complications.

Also known as:

Key symptoms:

Unusually low platelet count in the newbornTiny red or purple pinpoint spots on the skin (petechiae)Bruising that appears easily or without clear causeBleeding from the belly button, circumcision site, or other woundsBleeding inside the brain (intracranial hemorrhage)Seizures in the newbornSwelling or bulging of the soft spot on the baby's headPale or yellowish skinUnusual sleepiness or difficulty waking the babyPoor feeding

Clinical phenotype terms (17)— hover any for plain English
Neonatal alloimmune thrombocytopeniaHP:0004809Spontaneous hematomasHP:0007420CephalohematomaHP:0012541MelenaHP:0002249EcchymosisHP:0031364Subarachnoid hemorrhageHP:0002138Bilateral sensorineural hearing impairmentHP:0008619
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗NORD ↗

FDA & Trial Timeline

5 events
Feb 2025A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC — PHASE3

TrialRECRUITING
Nov 2024A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Janssen Research & Development, LLC — PHASE3

TrialRECRUITING
Jun 2021The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia

Karolinska Institutet

TrialRECRUITING
Aug 2019Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation

Boston Children's Hospital

TrialRECRUITING
Apr 2013Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates

Boston Children's Hospital

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Fetal and neonatal alloimmune thrombocytopenia.

3 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

3 recruitingView all trials with filters →
Phase 32 trials
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Phase 3
Actively Recruiting
PI: Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC) · Sites: Birmingham, Alabama; Sacramento, California +20 more · Age: 1845 yrs
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Phase 3
Actively Recruiting
PI: Janssen Research & Development, LLC Clinical Trial (Janssen Research & Development, LLC) · Sites: Leuven; Recife +19 more · Age: 1845 yrs
Other1 trial
The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia
Actively Recruiting
PI: Emöke Deschmann, MD, PhD (Karolinska Institutet) · Sites: Boston, Massachusetts; Boston, Massachusetts +6 more

Specialists

23 foundView all specialists →
MM
Michaela Köhm, MD
Specialist
PI on 1 active trial
NC
Nina Cooper
LAWRENCEVILLE, GA
Specialist
3 Fetal and neonatal alloimmune thrombocytopenia publications
HT
Heidi Tiller
Specialist
6 Fetal and neonatal alloimmune thrombocytopenia publications
TV
Thijs W de Vos
Specialist
5 Fetal and neonatal alloimmune thrombocytopenia publications
EL
Enrico Lopriore
Specialist
5 Fetal and neonatal alloimmune thrombocytopenia publications
GB
Gregor Bein
Specialist
4 Fetal and neonatal alloimmune thrombocytopenia publications
DO
Dick Oepkes
Specialist
4 Fetal and neonatal alloimmune thrombocytopenia publications
JK
Jens Kjeldsen-Kragh
Specialist
4 Fetal and neonatal alloimmune thrombocytopenia publications
SW
Sandra Wienzek-Lischka
Specialist
3 Fetal and neonatal alloimmune thrombocytopenia publications
RK
Rick Kapur
Specialist
3 Fetal and neonatal alloimmune thrombocytopenia publications
RB
Richard L Berkowitz
Specialist
2 Fetal and neonatal alloimmune thrombocytopenia publications
BC
Brian R Curtis
Specialist
2 Fetal and neonatal alloimmune thrombocytopenia publications
MH
Masja de Haas
Specialist
6 Fetal and neonatal alloimmune thrombocytopenia publications
DP
Dick Oepkes, Prof MD PhD
Specialist
PI on 1 active trial
UD
Urielle Desalbres
Specialist
PI on 21 active trials1 Fetal and neonatal alloimmune thrombocytopenia publication
MP
Masja de Haas, Prof MD PhD
Specialist
PI on 1 active trial
EP
Ellen vd Schoot, Prof MD PhD
Specialist
PI on 1 active trial
EH
Emilie L Vander Haar
WEST CHESTER, OH
Specialist
2 Fetal and neonatal alloimmune thrombocytopenia publications
LP
Leendert Porcelijn
Specialist
3 Fetal and neonatal alloimmune thrombocytopenia publications
CS
C Ellen van der Schoot
WINDSOR, CT
Specialist
5 Fetal and neonatal alloimmune thrombocytopenia publications
OP
Ovidiu Bedreag, Assoc Prof
Specialist
PI on 1 active trial
AP
Alexandru Florin Rogobete, PhDs
Specialist
PI on 1 active trial
ED
Emöke Deschmann
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Fetal and neonatal alloimmune thrombocytopenia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Fetal and neonatal alloimmune thrombocytopeniaForum →

No community posts yet. Be the first to share your experience with Fetal and neonatal alloimmune thrombocytopenia.

Start the conversation →

Latest news about Fetal and neonatal alloimmune thrombocytopenia

1 articles
NewsRSSApr 22, 2026
Test Your Knowledge About Life Expectancy in FNAIT
This article invites people to take a quiz about life expectancy in FNAIT (Fetal and Neonatal Alloimmunization Thrombocytopenia), a rare blood disorder that aff
See all news about Fetal and neonatal alloimmune thrombocytopenia

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What platelet antigen mismatch caused this, and what does that mean for future pregnancies?,Should my partner and I be tested before we try to have another baby?,What is the risk that a future baby will be affected, and will it be more or less severe?,What monitoring and treatment would you recommend during my next pregnancy to protect the baby?,Does my baby need a brain scan, and what follow-up is needed if there was any bleeding?,Are there any activity restrictions or precautions while my baby's platelet count is still low?,Are there any clinical trials or research studies we should know about?

Common questions about Fetal and neonatal alloimmune thrombocytopenia

What is Fetal and neonatal alloimmune thrombocytopenia?

Fetal and neonatal alloimmune thrombocytopenia (FNAIT), also called neonatal alloimmune thrombocytopenia (NAIT or NAT), is a blood condition that affects babies before or shortly after birth. It happens when a mother's immune system makes antibodies against proteins on her baby's platelets — the tiny blood cells that help stop bleeding. This occurs because the baby inherits platelet proteins from the father that the mother does not have. Her immune system sees these proteins as foreign and attacks them, lowering the baby's platelet count to dangerously low levels. The most serious risk is ble

How is Fetal and neonatal alloimmune thrombocytopenia inherited?

Fetal and neonatal alloimmune thrombocytopenia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Fetal and neonatal alloimmune thrombocytopenia typically begin?

Typical onset of Fetal and neonatal alloimmune thrombocytopenia is neonatal. Age of onset can vary across affected individuals.

Are there clinical trials for Fetal and neonatal alloimmune thrombocytopenia?

Yes — 3 recruiting clinical trials are currently listed for Fetal and neonatal alloimmune thrombocytopenia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Fetal and neonatal alloimmune thrombocytopenia?

23 specialists and care centers treating Fetal and neonatal alloimmune thrombocytopenia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.